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Abstract 
Background: Current multiparametric MRI (mp-MRI) in routine clinical practice has poor-to-moderate diagnos-
tic performance for transition zone prostate cancer. The aim of this study was to evaluate the potential diagnostic 
performance of novel 1H magnetic resonance spectroscopic imaging (MRSI) using a semi-localized adiabatic selective 
refocusing (sLASER) sequence with gradient offset independent adiabaticity (GOIA) pulses in addition to the routine 
mp-MRI, including T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI) and quantitative dynamic contrast 
enhancement (DCE) for transition zone prostate cancer detection, localization and grading.
Methods: Forty-one transition zone prostate cancer patients underwent mp-MRI with an external phased-array 
coil. Normal and cancer regions were delineated by two radiologists and divided into low-risk, intermediate-risk, and 
high-risk categories based on TRUS guided  biopsy results. Support vector machine models were built using different 
clinically applicable combinations of T2WI, DWI, DCE, and MRSI. The diagnostic performance of each model in cancer 
detection was evaluated using the area under curve (AUC) of the receiver operating characteristic diagram. Then 
accuracy, sensitivity and specificity of each model were calculated. Furthermore, the correlation of mp-MRI parame-
ters with low-risk, intermediate-risk and high-risk cancers were calculated using the Spearman correlation coefficient.
Results: The addition of MRSI to T2WI + DWI and T2WI + DWI + DCE improved the accuracy, sensitivity and specific-
ity for cancer detection. The best performance was achieved with T2WI + DWI + MRSI where the addition of MRSI 
improved the AUC, accuracy, sensitivity and specificity from 0.86 to 0.99, 0.83 to 0.96, 0.80 to 0.95, and 0.85 to 0.97 
respectively. The (choline + spermine + creatine)/citrate ratio of MRSI showed the highest correlation with cancer risk 
groups (r = 0.64, p < 0.01).
Conclusion: The inclusion of GOIA-sLASER MRSI into conventional mp-MRI significantly improves the diagnostic 
accuracy of the detection and aggressiveness assessment of transition zone prostate cancer.
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Background
Prostate cancer (PCa) is the most common malignancy 
and the fourth leading cause of cancer death among 
males worldwide [1]. Almost 30% of PCa lesions occur 
in the transition zone (TZ) [2]. TZ cancer has a relatively 
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low Gleason score (GS), local stage and biochemical 
recurrence rate in comparison with peripheral zone (PZ) 
PCa [3]. Due to difficulties in localizing TZ by digital 
rectal exam, sampling of TZ cancer by routine transrec-
tal ultrasound (TRUS)-guided biopsy and low  specific-
ity of prostate specific antigen (PSA) as cancer marker, 
there is a high potential risk for missing TZ lesions [4]. 
Magnetic resonance imaging (MRI) with its non-invasive 
soft tissue contrast capability has the potential to over-
come these limitations for the detection of TZ cancer [5]. 
T2-weighted imaging (T2WI) provides the best anatomi-
cal images of TZ and PZ. However, TZ often contains 
benign prostatic hyperplasia (BPH), which may have 
low-signal intensity on T2WI similar to that of cancer [6]. 
Furthermore, the clinical application of multiparamet-
ric MRI (mp-MRI) including T2WI, diffusion-weighted 
imaging (DWI) and dynamic contrast enhanced (DCE) 
imaging as defined by the Prostate Imaging Reporting 
and Data System (PI-RADS V2) has shown moderate 
diagnostic performance for TZ cancer [7]. The overlap 
of apparent diffusion coefficient (ADC) values between 
cancer and BPH in TZ is the main limitation of DWI [8]. 
DCE has a minor role in TZ cancer detection because 
BPH in TZ can be highly vascularized and shows rapid 
and high level enhancement similar to PCa [9]. The diag-
nostic potential of proton MR spectroscopic imaging 
(MRSI) in combination with anatomical and functional 
MRI for the improvement of PCa detection, localization 
and characterization has already been demonstrated [10, 
11]. Point-resolved spectroscopy (PRESS) is the most 
commonly used pulse sequence for prostate MRSI mainly 
because of its commercial availability, but it suffers from 
chemical shift displacement error, long acquisition time 
and bad slice profiles, which causes unpredictable lipid 
signal contamination. These problems were addressed 
by using a semi-localized adiabatic selective refocus-
ing pulse sequence (sLASER) with gradient-modulated 
offset-independent adiabatic (GOIA) pulses (GOIA-
sLASER), which resulted in much cleaner MR spectra of 
the prostate [12]. To our knowledge, there have been no 
reports on the diagnostic performance of MRSI GOIA-
sLASER within routine clinical prostate mp-MRI exams.
The purpose of this study was to evaluate the diagnos-
tic performance of individual and combined mp-MRI 
parameters, employed for PI-RADS evaluations, and 
GOIA-sLASER MRSI using an external phased-array coil 
for TZ cancer detection, localization and grading.
Methods
Patients
In total, 45 patients with biopsy-proven TZ cancer and 
one biopsy-negative subject were consecutively enrolled 
in this study. Four patients were excluded from the 
study due to  poor-quality data.  The study protocol was 
approved by the local Human Research Ethics Commit-
tee and each patient signed a consent form before the 
MRI examination. Depending on prostate gland size, at 
least sixteen TRUS guided biopsy cores were obtained 
from each patient between six to eight weeks before the 
MRI examination.
MRI acquisition protocol
Prostate mp-MRI was performed on a whole-body 3  T 
MR scanner using an eighteen-channel phased-array 
coil (MAGNETOM Prisma, Siemens Healthcare, Erlan-
gen, Germany) and without endorectal coil. The mp-
MRI protocol included axial, coronal and sagittal T2WI, 
DWI and three-dimensional (3D) MRSI. The last step 
in this protocol was DCE MRI for which paramagnetic 
gadolinium (Gadovist®, Bayer Heathcare Pharmaceuti-
cals, Berlin, Germany) was administered as bolus injec-
tion of 0.1  mmol/kg body weight with a power injector 
at 2.5 mL/s and followed by a 15-mL saline flush. A DCE 
time series was acquired with a T1-weighted sequence 
including 4 baseline acquisitions before the injection. 
Details of the mp-MRI acquisition parameters are sum-
marized in Table 1.
MRI prostate mapping and pre‑processing
Bias correction, noise reduction and intensity standardi-
sation were applied on T2WI [13].
ADC maps were calculated inline from DWI’s using 
a mono-exponential fitting of b-values 0, 400, 800 and 
1600 s/mm2 in syngo software.
DCE-MR images were processed by a Siemens dedi-
cated Tissue4D module for dynamic analysis of DCE 
MR with an implementation of the Tofts model and an 
assumed arterial input function (AIF) [14]. After motion 
correction, optimal AIFs were selected from slow, inter-
mediate and fast population-averaged options, consid-
ering individual volume of interest (VOI) curves. The 
quantitative variables derived from T1 maps were the 
volume transfer constant  (Ktrans,  min−1), the  rate con-
stant  (Kep,  min−1) and the area under gadolinium curve 
(iAUGC, mmol min/L).
Citrate (Cit), creatine (Cr), choline (Cho) and sper-
mine (Spm) tissue concentrations within a voxel were 
determined by the automated peak fitting algorithm 
LCModel (Version 6.3-1L) using metabolite basis sets. 
Two Cit ratios, ((Cho + Spm + Cr)/Cit and Cho/Cit), and 
the Cho/Cr ratio were calculated for each voxel within a 
selected region (vide infra).
Tissue segmentation
All patients underwent at least 16-core (S16C) transrec-
tal and transperineal ultrasound-guided biopsy using a 
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reusable biopsy gun. Two independent radiologists, one 
with more than twenty years’ experience (P.L.) and one 
with thirteen years’ experience (S.S.) in prostate radiol-
ogy, evaluated all MRI images in conjunction with the 
biopsy reported cancer locations. Radiologists visually 
matched ADC maps, baseline images (b-value = 0  s/
mm2), and corresponding T2WI slice locations and gland 
anatomy (apex, mid-gland area and base).
In total, 61 cancer regions with biopsy-proven positive 
TZ cancer (1–3 cancer regions per patient) were manu-
ally delineated on T2WI by the two radiologists and these 
were subsequently co-registered to the corresponding 
ADC, DCE and MRSI maps. To maximize the identifi-
cation accuracy of the cancer regions, only concurrent 
reporting of cancer ROIs was used. Then, the two radiol-
ogists in consensus selected 73 normal regions from TZ 
with negative biopsies (1–2 normal regions per patient). 
Each cancer or normal region was selected over one ROI 
on a single slice or multiple ROIs on multiple slices for 
each patient. The ROIs on multiple slices for each tissue 
were summarised per mean value to eliminate bias.
Assessment of histologic tumor grade
Cancerous tissues were sub-divided according to GS into 
three main risk groups to evaluate the value of mp-MRI 
parameters to discriminate between different cancer 
grades. These risk groups are (a) 37 regions with GS of 
3 + 3 as low-risk, (b) 9 regions with GS of 3 + 4 as inter-
mediate-risk and (c) 15 regions with GS ≥ 4 + 3 as high-
risk. Each cancer region parameter on mp-MRI maps 
was subsequently correlated to the matching GS group 
based on biopsy results.
Classification and statistical analysis
A non-parametric Mann–Whitney U-test with Bonfer-
roni correction was performed for each pair group to 
determine significant difference between the mean values 
of normal and cancer regions of mp-MRI parameters.
We developed a machine learning platform for mp-
MRI including support vector machine (SVM) classifica-
tions with a radial basis function kernel (RBF-SVM) and 
area under receiver operator characteristic (ROC) analy-
ses using an in-house Matlab routine to evaluate the diag-
nostic performance of models with different parametric 
combinations: T2WI + DWI, T2WI + DWI + DCE, 
T2WI + DWI + MRSI, and T2WI + DWI + DCE + MRSI. 
Mp-MRI parameters involved were ADC,  Ktrans,  Kep, 
iAUGC, (Cho + Spm + Cr)/Cit, Cho/Cit and Cho/Cr. 
Models were developed with mp-MRI parameters with 
a statistically significant difference between each pair 
group. The sensitivity, specificity and overall accuracy of 
each classifier are reported.
The correlation between risk groups (low-risk, inter-
mediate-risk and high-risk) and mp-MRI parameters was 
measured with Spearman correlation coefficient (r) (IBM 
SPSS). Then, mp-MRI parameters with |r|≥ 0.25 were 
used to develop RBF-SVM models between cancer risk 
groups. These models were used to evaluate the diagnos-
tic performance of mp-MRI parameters to differentiate 
cancer risk groups. All evaluations were based on biopsy 
results.
Table 1 MRI acquisition parameters for prostate multiparametric MRI (mp-MRI)
TR repetition time, TE echo time, FOV field of view, TSE turbo spin echo, EPI echo planar imaging, VIBE volumetric interpolated breath-hold examination, GOIA-sLASER 
gradient offset independent adiabaticity with semi-localized adiabatic selective refocusing, NA not available/not applicable
T2WI (Axial) T2WI (Coronal) T2WI (Sagittal) DWI DCE MRSI
Sequence 2D TSE 2D TSE 2D TSE EPI 3D VIBE GOIA-sLASER
TR (ms) 4300 3620 4500 3400 4.88 820
TE (ms) 102 104 90 53 1.77 88
Averages 2 3 3 16 1 4
Flip angle
(degree)
160 160 128 90 15 90–4 × 180
Thickness (mm) 3 3 3 3 3 7
Gap (mm) 0 0 0 0 0 0
FOV (mm) 200 × 200 200 × 200 240 × 240 256 × 256 260 × 260 84 × 84 × 70
b-value (s/mm2) NA NA NA 0, 400, 800 and 1600 NA NA
Temporal resolution (s) NA NA NA NA 4.8 NA
Matrix 448 × 448 × 30 448 × 448 × 30 320 × 320 × 24 84 × 128 × 24 192 × 192 × 24 12 × 12 × 10
Spatial resolution  (mm3) 0.45 × 0.45 × 3 0.45 × 0.45 × 3 0.75 × 0.75 × 3 2 × 2 × 3 1.35 × 1.35 × 3 7 × 7 × 7
Acquisition time (min) 3.19 4.51 4.05 6.26 6.23 8.42
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Optimal kernel parameters for RBF-SVM were calcu-
lated by a grid search approach [15]. The performance of 
the SVM classification models was determined by leave-
one-out cross-validation.
McNemar tests were used for pairwise comparisons 
of sensitivity and specificity between different mp-MRI 
models, while Delong test was used to compare the area 
under curves (AUCs). A p value < 0.05 was considered 
statistically significant.
Results
Multiparametric MRI of prostate cancer patients
To avoid inclusion of low-quality data, the MR data 
from four patients were excluded from the study as 
they showed distortion artefacts on DWI and had a 
 FWHMwater > 50 Hz for the whole prostate gland, related 
to patients’ movements and motion during scanning. 
Clinical and demographic data of the remaining 41 
patients are summarized in Table 2.
Employing a phased-array receive coil (without an 
endorectal coil), the application of GOIA-sLASER MRSI 
to the prostate produced MR spectra showing well-
resolved metabolite signals with adequate SNR (Figs. 1G, 
2G and 3G).
Figure  1 shows MR data of a prostate which was 
biopsy-proven negative for PCa. The negative-biopsy 
areas in the left and right  TZ appeared as low-signal 
intensity on T2WI and the ADC map (restricted diffu-
sion) and as high-signal intensity on high b-value DWI, 
 Ktrans and iAUGC maps (Fig.  1A–D, F). However, these 
areas appeared as normal on  Kep maps (Fig.  1E). More-
over, the MR spectra, derived from the MRSI exam, of 
these (biopsy cancer negative) ROIs exhibited high Cit 
and low Cho signals (Fig. 1G) representing normal pros-
tate tissue and thus providing vital information indicative 
of the absence of cancer tissue.
Figure  2 shows data of an mp-MRI exam obtained 
from a patient with a region in the prostate with low-risk 
cancer (GS = 3 + 3) in the left TZ ( arrows). This region 
appeared as low-signal intensity on T2WI and on the 
ADC map (Fig. 2A, B) and high-signal intensity on high 
b-value DWI and on pharmacokinetic maps derived from 
DCE (Fig. 2C–F). The MR spectra obtained from this ROI 
exhibited relatively high Cho signals and low Cit signals 
(Fig. 2G, right). A negative biopsy area in the right TZ of 
the prostate of this patient (arrows) also appeared as low-
signal intensity on T2WI and the ADC map (restricted 
diffusion) and as high-signal intensity on high b-value 
DWI and pharmacokinetic maps (Fig.  2A–F), all sug-
gesting the presence of cancer tissue. However, the MR 
spectra of this region, derived from the 3D MRSI exam, 
exhibited normal high Cit signals and low Cho signals 
(Fig.  2G, left), in complete agreement with the biopsy 
results that this region contains no cancer.
In patients with high-risk TZ prostate cancers, tumor 
tissue presented as low-signal intensity on T2WI and 
ADC maps and high-signal intensity on high b-value 
DWI and pharmacokinetic parameter maps of DCE 
exams (Fig.  3A–F). Normal TZ tissue showed higher 
signal intensity on ADC maps (Fig. 3B). However, quan-
titative DCE parameters maps generally showed incon-
clusive enhancements making them ineffective in the 
differentiation of central cancer tissue from normal tis-
sue. MRSI spectral maps of the entire prostate showed 
low-signal intensity levels for Cit and high-intensity lev-
els for Cho in tumor areas (Fig. 3G, left), whereas normal 
TZ tissue showed relatively high levels of Cit and low lev-
els of Cho (Fig. 3G, right).
In addition, in five patients with both TZ and PZ PCa, 
high quality MR spectra were obtained for PZ. Figure 4 is 
an example of a spectral map of the entire prostate gland 
of a man with biopsy-proven PZ and TZ PCa lesions.
Table 2 Demographic and clinical data of the prostate cancer patients enrolled in this study (A) and Gleason score of biopsies (B)
PSA prostate specific antigen
A) Mean ± SD Range
Age (years) 66.31 ± 7.19 53 – 81
PSA (ng/mL) 7.82 ± 3.91 2.5 – 18.9
Prostate volume  (cm3) 45.01 ± 17.23 22.02 – 91.11
B) Biopsy Gleason Score Number of biopy‑proven cancer tissue (total = 61) % of total
3 + 3 37 60.7
3 + 4 9 14.7
4 + 3 7 11.5
4 + 4 6 9.8
4 + 5 2 3.3
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The mean and standard deviation values of mp-MRI 
parameters in TZ cancer and normal tissue are given in 
Table  3. ADC values derived from DWI measurements 
were significantly lower in cancerous tissues than in nor-
mal tissues (p < 0.01). The pharmacokinetic parameters 
 Ktrans,  Kep and iAUGC, derived from DCE MRI, increased 
in cancer tissues compared to normal tissues (p < 0.05). 
The mean values of (Cho + Spm + Cr)/Cit, Cho/Cit and 
Cho/Cr from the MRSI examinations in cancer ROIs 
were significantly higher than in normal tissues (p < 0.01). 
There was also a significant difference in all metabolite 
ratios of cancer compared to normal tissues in PZ 
(p < 0.01).
Individual and combined MR imaging metrics to detect 
cancer tissue
Figure  5 shows ROC curves of final RBF-SVM mod-
els for each pair of groups with and without MRSI (left 
side). These results demonstrated that MRSI signifi-
cantly improved the AUC (p < 0.01) and also sensitiv-
ity and specificity (p < 0.01) in the detection of TZ 
cancers (bar charts on right side of Fig.  5). There was 
Fig. 1 Multiparametric MRI of the prostate of a 58-year-old man with an elevated serum PSA level of 6.8 ng/mL and cancer-negative biopsy results. 
A T2WI with low-signal intensity areas in the left and right transition zone (arrows) which were biopsy negative for cancer. B ADC map showing 
low-signal intensity for the same areas. High-signal intensity for these areas were seen on C high b-value DWI and on pharmacokinetic maps of 
D  Ktrans, E  Kep, and F iAUGC. G Middle: MRSI grid and color-coded map overlaid on T2WI. The spectra in the yellow box at the right side and in the 
green box at the left side represent voxels from histopathology confirmed normal tissue (circles)
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no significant difference between AUC, sensitivity and 
specificity of T2WI + DWI and T2WI + DWI + DCE 
(p > 0.05) and also between T2WI + DWI + MRSI and 
T2WI + DWI + DCE + MRSI models (p > 0.05).
For models without MRSI, T2WI + DWI achieved the 
highest AUC, accuracy and specificity at 0.86, 0.83 and 
0.85, respectively and the T2WI + DWI + DCE model 
yielded the highest sensitivity at 0.84. The accuracy and 
specificity of the T2WI + DWI model was higher than 
that of the T2WI + DWI + DCE model.
For models including MRSI metabolite ratios that 
performed significantly better than without these ratios 
(p < 0.05), the T2WI + DWI + MRSI model achieved the 
highest AUC, accuracy, sensitivity and specificity at 0.99, 
0.96, 0.95 and 0.97, respectively. There was no improve-
ment in detection accuracy by adding DCE to the 
T2WI + DWI + MRSI model. The AUC, accuracy, sensi-
tivity and specificity of all RBF-SVM models are summa-
rized in Table 4.
Fig. 2 Multiparametric MRI of the prostate of a 68-year-old man with a serum PSA level of 4.3 ng/ml, who was diagnosed with a biopsy-proven 
Gleason 3 + 3 cancer region in the left of the transition zone (arrows). The area on the right of the transition zone (arrows) had a cancer-negative 
biopsy outcome. A T2WI, B ADC map, C high b-value DWI, pharmacokinetic maps of calculated D  Ktrans, E  Kep, F iAUGC and G MRSI grid and 
color-coded map overlaid on T2WI, with the red circle representing a voxel with cancer (spectrum in box at the left hand side) and the green circle 
representing a voxel with normal tissue (spectrum in box at the right hand side)
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Correlation of MR parameter values with tumor 
aggressiveness
Correlation coefficients for the normalized T2WI, and 
the pharmacokinetic DCE parameters  Kep, and iAUGC 
with GS risk groups were very low and non-significant 
(|r|< 0.25, p > 0.05). A low, but significant, correlation 
was found for  Ktrans (r = 0.29, p < 0.05). Compared to 
the DCE parameters, the average ADC demonstrated 
a better correlation with the different aggressiveness 
groups (r = -0.51, p < 0.01). The (Cho + Spm + Cr)/Cit 
derived from MRSI had the highest correlation with 
tumor aggressiveness (r = 0.64, p < 0.01). The correla-
tion coefficients of Cho/Cit and Cho/Cr with different 
risk groups were r = 0.32 (p < 0.05) and r = 0.28 (p < 0.05), 
respectively. Figure  6 shows a boxplot representing the 
ADC and (Cho + Spm + Cr)/Cit parameters for nor-
mal, low-risk, intermediate-risk, and high-risk tissues. 
Higher grade TZ cancer tissue was associated with lower 
ADC values (Fig.  6A) and higher (Cho + Spm + Cr)/Cit 
ratios (Fig. 6B).
Ktrans and ADC values were used to build RBF-SVM 
models between different risk groups (normal vs 
Fig. 3 Multiparametric MRI of the prostate of a 59-year-old patient with an elevated serum PSA level of 12.1 ng/ml, who was diagnosed with a 
biopsy-proven prostate cancer with Gleason 4+4 in the right side of the transition zone (arrows). A T2WI, B ADC map, C high b-value DWI, and 
pharmacokinetic maps of D  Ktrans, E  Kep,and F iAUGC. G MRSI grid and color-coded map of (Cho + Spm + Cr)/Cit values overlaid on T2WI, with red 
circle identifying a voxel in cancer region and green circle for a voxel in normal tissue. Left: MR spectrum from voxel of cancer tissue spectrum (red 
box). Right: MR spectrum from voxel of normal tissue (green box)
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cancer, low-risk vs high-risk cancer, low-risk vs inter-
mediate-risk cancer and intermediate-risk vs high-risk, 
(p < 0.05)). Then, these models were extended by add-
ing MRSI metabolite ratios to the  Ktrans and ADC val-
ues. The ROC curve of the final RBF-SVM model for 
each set of two risk groups was plotted and AUC’s were 
determined to compare the diagnostic performance 
of each model (Fig.  7). The results demonstrate that 
metabolite ratios improve the AUC, sensitivity, speci-
ficity and accuracy for the discrimination of low-risk 
vs high-risk cancer and low-risk vs intermediate-risk 
cancer groups (right side of Fig.  7). For instance, the 
AUC in discriminating low-risk from high-risk cancer 
significantly increased by adding metabolite ratios from 
MRSI to the combination of ADC and  Ktrans from 0.64 
to 0.86 (p < 0.01). There was no significant difference 
between the performance of models for intermediate-
risk vs high-risk cancer with and without MRSI metab-
olite ratios (p > 0.05).
Discussion
A combination of T2WI, DWI and DCE is the most 
commonly used mp-MRI set in routine clinical exams 
for the management of patients with localized PCa as 
defined by PI-RADS V2 guidelines [16]. Numerous stud-
ies evaluated a quantitative combination of these mp-
MRI methods to investigate their ability for the detection, 
localization, grading and staging of cancer in the pros-
tate [16–18]. Most of these studies reported poor-to-
moderate accuracy and reproducibility of mp-MRI for 
localization of PCa in TZ as compared to PZ [7, 19–21]. 
TZ of patients suspected of having PCa frequently con-
tain regions of glandular BPH and stromal BPH, next to 
other tissues such as (hypertrophic) anterior fibromuscu-
lar stroma [22]. In the diagnosis of TZ cancer, T2WI is 
usually emphasized more than DWI [23]. Because BPH 
can appear as hyperintense nodules and stromal BPH 
as hypointense nodules on T2WI, it remains challeng-
ing to differentiate TZ cancer from normal tissue using 
T2WI alone [24]. Combining T2WI and DWI generally 
improves TZ tumor detection and localization, although 
these results are variable [21, 25, 26].
Our results indicate that the combination of T2WI and 
ADC’s derived from DWI exams including high b-value 
(1600  s/mm2), using RBF-SVM classification, improves 
the diagnostic accuracy of TZ cancer compared to T2WI 
alone. This result is similar to that reported previously 
for TZ [19, 27–29]. Some studies demonstrated better 
Fig. 4 T2WI images with spectroscopy grid (middle panel) of a 72-year-old patient with an elevated serum PSA level of 14.5 ng/ml, who was 
diagnosed with biopsy proven cancer lesions with Gleason 4 + 3 in the left peripheral zone and a Gleason 3 + 3 lesion in the left transition zone. The 
red circle identifies a voxel in cancer region (right hand side spectrum) and green circle identifies a voxel in normal tissue of the peripheral zone (left 
hand side spectrum)
Table 3 Mean ± standard deviation of multiparametric 
magnetic resonance imaging (mp-MRI) parameters for 
discrimination of cancer and normal tissue in the central gland
ADC apparent diffusion coefficient, Ktrans the volume transfer constant, 
Kep the rate constant , iAUGC  the area under gadolinium curve,  Cho choline,  
Spm spermine, Cr creatine, Cit citrate




ADC  (10–6  mm2/s) 1112.42 ± 138.83 871.10 ± 149.61  < 0.01
Ktrans  (min−1) 0.14 ± 0.08 0.24 ± 0.10  < 0.01
Kep  (min
−1) 0.65 ± 0.38 1.12 ± 0.53  < 0.01
iAUGC (mmol.min/L) 2.61 ± 1.04 3.15 ± 1.31  < 0.05
(Cho + Spm + Cr)/Cit 0.23 ± 0.09 1.60 ± 1.12  < 0.01
Cho/Cit 0.16 ± 0.08 0.82 ± 0.38  < 0.01
Cho/Cr 1.28 ± 0.68 2.94 ± 0.87  < 0.01
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results for TZ cancer detection by combining T2WI and 
higher b-value DWI (b-value = 2000s/mm2) [21, 30].
For the combination of T2WI and DCE, some reports 
suggested a potential value for DCE parameters in 
the diagnosis of TZ cancer, but other studies failed to 
find any added benefit [20, 31]. Our results showed no 
improvement in AUC, accuracy, and sensitivity in detect-
ing TZ cancer by adding DCE to T2WI + DWI. This 
agrees with studies in which the detection of TZ can-
cer was not improved by adding DCE to T2WI [31, 32]. 
However, a quantitative assessment with linear regres-
sion indicated that washout in DCE may contribute to 
detection efficiency [17]. T2WI + DWI + DCE achieved 
higher sensitivity and lower accuracy and specificity than 
T2WI + DWI and T2WI + DCE models. This can be 
attributed to the marked hyper-vascularity of BPH nod-
ules, which can show rapid enhancement as well as early 
washout. However, together these MRI methods are still 
limited for accurate detection and localization of PCa in 
TZ. An alternative approach to this is adding MRSI to 
mp-MRI exams, as prescribed in the original PI-RADS 
(V1) guidelines. Our results (Table 4 and Fig. 5) suggest 
that DCE can be replaced by MRSI using a GOIA-sLA-
SER sequence to detect TZ PCa.
It is well established that MRSI can provide valuable 
metabolic information for the non-invasive assessment of 
PCa [10, 11]. Several studies have concluded that adding 
MRSI to mp-MRI exams improves the diagnostic perfor-
mance of detecting cancer in TZ [33, 34]. Also in a multi-
centre trial MRSI was shown to be able to discriminate 
between cancer and normal TZ tissues [35]. Most of the 
previous prostate MRSI studies employed PRESS with 
standard RF pulses at TE > 100  ms, representing a T2 
penalty on all signals of interest. Due to the suboptimal 
Fig. 5 Results of support vector machine analysis to discriminate cancer from normal tissue in the prostate transition zone. Left: ROC plot of 
combinations of multiparametric MRI values. T2WI + DWI is in blue and T2WI + DWI + DCE in green. Without MRSI is represented by a dashed-line 
and with MRSI by a solid-line. Only multiparametric MRI parameters with statistically significant differences between cancer and normal tissues 
(p < 0.05) were used for classification. Right: Bar charts of AUC values, sensitivity and specificity of the corresponding RBF-SVM models. McNemar 
test was used for pairwise comparison of sensitivity and specificities of models and Delong test was calculated for pairwise comparison of AUC of 
models. **p < 0.01
Table 4 Area under receiver operating characteristic curve (AUC) and diagnostic accuracy, sensitivity and specificity of detecting 
central cancers by T2WI (standardized T2WI signal intensity), DWI (ADC), DCE  (Ktrans,  Kep and iAUGC) and MRSI ((Cho + Spm + Cr)/Cit, 
Cho/Cit and Cho/Cr)
T2WI T2-weighted imaging, DWI diffusion weighted imaging, DCE dynamic contrast enhancement, MRSI magnetic resonance spectroscopic imaging, CI confidence 
intervals
Model AUC (%95 CI) Accuracy Sensitivity Specificity
T2WI + DWI 0.86 (0.75–1.00) 0.83 (111/134) 0.80 (49/61) 0.85 (62/73)
T2WI + DWI + DCE 0.83 (0.70–1.00) 0.80 (107/134) 0.84 (51/61) 0.77 (56/73)
T2WI + DWI + MRSI 0.99 (0.97–1.00) 0.96 (129/134) 0.95 (58/61) 0.97 (71/73)
T2WI + DWI + DCE + MRSI 0.98 (0.95–1.00) 0.95 (127/134) 0.95 (58/61) 0.94 (69/73)
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slice selection of standard RF pulses, causing unpredict-
able lipid signal contamination, and this T2 penalty, the 
added value of MRSI in mp-MRI of TZ was limited, in 
particularly when performed without using an endorectal 
coil [32].
The results of this study demonstrate that metabolic 
information derived from MRSI using GOIA-sLASER 
can accurately differentiate among low-risk and clini-
cally significant PCa in TZ. These results also indicate 
that adding MRSI data, acquired with a GOIA-sLASER 
sequence, to the routine clinical MRI exam can signifi-
cantly improve accuracy. The useful role of quantitative 
MRSI parameters in combination with functional param-
eters in TZ tumor detection has been acknowledged in 
the literature [33, 36] Using an RBF-SVM model gener-
ated from T2WI, ADC and the metabolite ratios, we 
obtained high values for AUC, accuracy, sensitivity and 
specificity for diagnostic separation of cancer from nor-
mal. A similar performance was reported for a quan-
titative study in which TZ PCa was discriminated from 
normal tissue using an endorectal coil at a TE = 85  ms 
and combining the Cho/Cr ratio from MRSI and ADC 
values [17].
In addition to the above, the correlation of mp-MRI 
parameters with low-risk (GS = 3 + 3), intermediate-risk 
(GS = 3 + 4) and high-risk (GS ≥ 4 + 3) cancers was inves-
tigated. Quantitative T2WI and pharmacokinetic DCE 
parameters did not correlate with the GS risk groups 
except for a low correlation with  Ktrans. This could be due 
to heterogeneity in tumor and normal tissue perfusion 
within TZ. The individual parameters (Cho + Spm + Cr)/
Fig. 6 Box plots of A ADC values and B 
(choline + spermine + creatine)/citrate ((Cho + Spm + Cr)/Cit) values 
of low-risk, intermediate-risk and high-risk transition zone prostate 
cancer tissues. The correlations with low-risk, intermediate-risk and 
high-risk prostate cancer tissues were evaluated with Spearman 
correlation coefficients. MR parameters of ROIs with normal transition 
zone tissue are shown for comparison (shaded)
Fig. 7 Results of support vector machine analysis to separate tumor aggressiveness classes. Left side: ROC curves of the six RBF-SVM models 
for low-risk vs high-risk cancer, low-risk vs intermediate-risk cancer and intermediate-risk vs high-risk cancer. A leave-one-out cross-validation 
technique was used for the combined ADC and  Ktrans (dashed line) and all the combined ADC,  Ktrans and metabolite ratios (solid line) with a 
significant difference between the two groups (p < 0.05). Right side: bar charts of AUC values, sensitivity and specificity of the corresponding 
RBF-SVM models. McNemar test was used for pairwise comparison of sensitivity and specificities of models and Delong test was calculated for 
pairwise comparison of AUC of models. **p < 0.01 and * p < 0.05
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Cit and ADC showed a moderate correlation with tumor 
aggressiveness. However, by combining  Ktrans, ADC and 
metabolite ratios in an RBF-SVM model we found an 
AUC of 0.86 for the discrimination of low-risk from high-
risk cancers.
The identification of low-risk vs high-risk cancers is of 
clinical importance as it may be used to avoid overtreat-
ment of patients with PCa. Comparable performances 
in the separation of low from high-risk cancer were 
obtained in studies of TZ using an endorectal coil and 
regression models involving ADC or DCE washout and 
metabolites from MRSI data [17, 37].
It is worth noting that 3D PRESS MRSI has been dem-
onstrated to give reproducible results at 1.5  T with an 
endorectal coil in a test-retest setting [38]. In later pub-
lications it was demonstrated that 3D GOIA-sLASER 
MRSI is superior to 3D PRESS MRSI [12] and that the 
former can be applied to the prostate without using an 
endorectal coil producing reliable metabolic values [39]. 
One of the limitations of the current study is the rela-
tively small number of intermediate and  high  grade TZ 
cancer patients for classification and prediction. Another 
limitation of this study is that the histopathological clas-
sification of lesions is based on a biopsy instead of on 
whole mount sections.
Conclusion
This study demonstrated that MRSI with a GOIA-sLA-
SER sequence in combination with structural T2WI and 
DWI offers a non-invasive and reliable tool to assess 
cancer tissue in the central prostate gland. We found 
that DCE has limited value in TZ cancer detection and 
localization. Although the correlation between cancer 
aggressiveness and metabolic ratios or ADC values was 
moderate, the combination of these two enabled a good 
separation between low-risk and high-risk cancers in TZ.
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